Liu Laura, Wu Wei-Chi, Yeung Ling, Wang Nan-Kai, Kuo Ya-Hui, Chao An-Ning, Chen Kuan-Jen, Chen Tun-Lu, Lai Chi-Chun, Hwang Yih-Shiou, Chen Yen-Po
Department of Ophthalmology, Chang Gung Memorial Hospital, No. 5, Fu-Shin Street, Kweishan, Taoyuan, 333, Taiwan.
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):72-7. doi: 10.3928/15428877-20091230-13.
To report the occurrence of ghost cell glaucoma after intravitreal injection of bevacizumab for the treatment of postoperative vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy (PDR).
Retrospective chart review from August 2006 to December 2007. Patients who had postoperative vitreous hemorrhage after vitrectomy for PDR and received an intravitreal injection of bevacizumab were enrolled in the study.
Eight eyes of 8 patients (mean age: 46 years) were included. After intravitreal injection of bevacizumab, 4 (50%) eyes had clearance of vitreous hemorrhage. Three eyes developed ghost cell glaucoma within 1 week after intravitreal injection of bevacizumab. Of these, intraocular pressure was controlled in 1 eye through the use of anti-glaucoma medication, whereas the other 2 eyes needed surgical intervention to lower intraocular pressure and subsequently clear the vitreous hemorrhage.
Intravitreal injection of bevacizumab may accelerate the clearance of postoperative vitreous hemorrhage in cases of PDR. However, a high incidence of ghost cell glaucoma was observed. Caution should be exercised when administering an intravitreal injection of bevacizumab for a postoperative vitreous hemorrhage after vitrectomy for PDR.
报告在增殖性糖尿病视网膜病变（PDR）玻璃体切除术后玻璃体内注射贝伐单抗治疗术后玻璃体出血后发生的幽灵细胞性青光眼。
对2006年8月至2007年12月的病历进行回顾性分析。纳入PDR玻璃体切除术后发生玻璃体出血并接受玻璃体内注射贝伐单抗的患者。
纳入8例患者的8只眼（平均年龄：46岁）。玻璃体内注射贝伐单抗后，4只眼（50%）的玻璃体出血得到清除。3只眼在玻璃体内注射贝伐单抗后1周内发生幽灵细胞性青光眼。其中，1只眼通过使用抗青光眼药物控制了眼压，而另外2只眼需要手术干预以降低眼压并随后清除玻璃体出血。
玻璃体内注射贝伐单抗可能会加速PDR患者术后玻璃体出血的清除。然而，观察到幽灵细胞性青光眼的发生率较高。在PDR玻璃体切除术后玻璃体内注射贝伐单抗治疗术后玻璃体出血时应谨慎。
